Cytokinetics Inc (NASDAQ: CYTK) is -34.27% lower on its value in year-to-date trading and has touched a low of $30.37 and a high of $110.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $53.15 in the last trading session, with the day’s gains setting it 1.73%.
Currently trading at $54.88, the stock is 1.32% and -0.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing 3.25% at the moment leaves the stock -14.44% off its SMA200. CYTK registered 52.66% gain for a year compared to 6-month loss of -23.31%. The firm has a 50-day simple moving average (SMA 50) of $54.992 and a 200-day simple moving average (SMA200) of $64.1393.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 1.52% gain in the last 1 month and extending the period to 3 months gives it a -4.37%, and is -3.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.39% over the week and 3.98% over the month.
Cytokinetics Inc (CYTK) has around 423 employees, a market worth around $6.46B and $3.13M in sales. Profit margin for the company is -17398.82%. Distance from 52-week low is 80.70% and -50.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.77%).
with sales reaching $1.19M over the same period.The EPS is expected to grow by 6.02% this year, but quarterly earnings will post -2.50% year-over-year. Quarterly sales are estimated to grow 214.80% in year-over-year returns.
Cytokinetics Inc (CYTK) Top Institutional Holders
471.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 118.60% of the company’s shares. The shares outstanding are 117.66M, and float is at 113.74M with Short Float at 15.23%. Institutions hold 118.00% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 14.3958% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 11.3056 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 11.2218% and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.985 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Blum Robert I, the company’s President & CEO. SEC filings show that Blum Robert I sold 5,000 shares of the company’s common stock on Oct 09 ’24 at a price of $55.61 per share for a total of $0.28 million. Following the sale, the insider now owns 0.4 million shares.
Still, SEC filings show that on Oct 01 ’24, Malik Fady Ibraham (EVP Research & Development) disposed off 7,300 shares at an average price of $52.10 for $0.38 million. The insider now directly holds 118,920 shares of Cytokinetics Inc (CYTK).
